ThromboGenics NV News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.10.13	ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA (PR Newswire)
17.10.13	Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole (PR Newswire)
17.10.13	Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole (PR Newswire)
01.10.13	Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH (PR Newswire)
01.10.13	Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH (PR Newswire)
30.09.13	ThromboGenics Establishes Level 1 ADR Program for US Investors (PR Newswire)
30.09.13	ThromboGenics Establishes Level 1 ADR Program for US Investors (PR Newswire)
05.09.13	ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema (PR Newswire)
05.09.13	ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema (PR Newswire)
02.09.13	UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
02.09.13	UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
29.08.13	ThromboGenics Business Update H1 2013 (PR Newswire)
29.08.13	ThromboGenics Business Update H1 2013 (PR Newswire)
16.08.13	Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion (PR Newswire)
16.08.13	Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion (PR Newswire)
02.08.13	Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
02.08.13	Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
28.11.12	KORREKTUR: INDEXÄNDERUNG/Umfangreiche Änderungen im Stoxx-600-Index (Dow Jones)
27.11.12	INDEXÄNDERUNG/Umfangreiche Änderungen im Stoxx-600-Index (Dow Jones)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.80	0.90 %	K V
Sonova Hldg	307.20	0.85 %	K V
Kuehne+Nagel Int	209.60	0.48 %	K V
Roche Hldg G	252.40	0.40 %	K V
Alcon	77.88	0.33 %	K V
Swiss Re	128.10	-0.54 %	K V
ABB	49.20	-0.69 %	K V
CieFinRichemont	121.45	-0.74 %	K V
Sika	226.80	-0.79 %	K V
Logitech Intl	70.68	-1.81 %	K V